Merck Serono hires global chief medical officer
pharmafile | January 10, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Merck Serono, hildemann
Merck Serono has appointed Steven Hildemann as global chief medical officer and head of its global Medical and Safety unit.
Hildemann will be based in Darmstadt, Germany, and report to Dr Annalisa Jenkins who is the head of R&D at the firm which is the biopharmaceutical division of Merck.
As CMO, Hildemann will be responsible for Global Medical Affairs, Global Drug Safety and External Scientific Affairs for Merck Serono. He will also serve as a member of the R&D executive leadership team.
“Dr Hildemann’s academic and industry experience is very impressive, and he is a valued addition to our organisation and the R&D leadership team,” said Jenkins. “His patient-centric focus is well-aligned with our commitment to delivering differentiated new medicines to people living with unmet medical needs around the world.”
Prior to joining the firm Hildemann was the associate VP, global Clinical Trial Operations Europe at MSD. In this capacity, he was responsible for the execution of all early- and late-stage development programmes.
Hildemann joined the pharma industry in 1998 as the country medical director cardiovascular for Searle in Germany. After a merger with Pharmacia, he progressed to positions of increasing responsibility and in 2002 moved to New Jersey in the US as the senior Global Medical director Cardiovascular for Pharmacia, and later Pfizer.
In 2004 Hildemann joined Schering-Plough as the country medical director in Germany. In this role, one of his joint responsibilities was the worldwide first launch of a novel combination in lipid-therapy in partnership with MSD.
In 2006, Hildemann led the design and full implementation of major global change efforts, such as global clinical harmonisation at Schering-Plough and global integration activities for MSD-Research-Laboratories during the merger of SP and MSD.
Hildemann succeeds Dr Florian Bieber in the CMO role at Merck Serono. Bieber left the firm in December 2013 to pursue other opportunities.
Related Content
Merck launches infertility programme in Uganda
Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching …
Merck rebrands as ‘science and technology’ company
Merck Group has rebranded to “reflect its transformation into a science and technology company”, and …
Merck KGaA reveals ASCO plans
Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, …
